CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
Study Number | Lead Group | Study Title | CIRB | Study Status |
---|---|---|---|---|
NRG-HN005 | NRG | A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
RTOG-BR-0118 | RTOG | A Phase III Study of Conventional Radiation Therapy Plus Thalidomide (NSC# 66847) Versus Conventional Radiation Therapy For Multiple Brain Metastases | Adult CIRB - Late Phase Emphasis | Completed |
EA6191 | ECOG-ACRIN | The BAMM2 (BRAF, Autophagy, MEK inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma | Adult CIRB - Late Phase Emphasis | Available to Open |
S0232 | SWOG | Double-Blinded Placebo Controlled Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients with Previously Untreated Multiple Myeloma who are Not Immediately Undergoing Autologous Stem Cell Transplant | Adult CIRB - Late Phase Emphasis | Completed |
10272 | NCORP-National Institutes of Health | A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer | Adult CIRB - Late Phase Emphasis | Available to Open |
E2603 | ECOG | A Double-blind; Randomized; Placebo-Controlled Phase III Trial of Carboplatin; Paclitaxel and Sorafenib Versus Carboplatin; Paclitaxel and Placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma | Adult CIRB - Late Phase Emphasis | Available to Open |
NRG-HN011 | NRG | A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN) | Adult CIRB - Late Phase Emphasis | Available to Open |
CALGB-30610 | CALGB | Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide | Adult CIRB - Late Phase Emphasis | Available to Open |
A031704 | Alliance | PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] | Adult CIRB - Late Phase Emphasis | Available to Open |
NRG-GY005 | NRG | A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone; or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian; fallopian tube; or primary peritoneal cancer (COCOS) | Adult CIRB - Late Phase Emphasis | Available to Open |